Venclexta Archives -

AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer

AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis

https://pharmaphorum.com/news/aacr-abbvie-says-mid-stage-trial-backs-navitoclax-in-myelofibrosis/

News/ News/ Sales and Marketing

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

Richard Staines AbbVie, acute myeloid leukaemia, AML, Roche, Venclexta 0 Comment

Combination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

https://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/

News/ News/ Oncology

New combination trial firms up Venclexta’s prospects in AML

Phil Taylor AbbVie, acute myeloid leukaemia, Oncology, Roche, Venclexta 0 Comment

AbbVie and Roche have been thrown a lifeline for their Venclexta drug in acute myeloid leukaemia (AML), just

New combination trial firms up Venclexta’s prospects in AML

https://pharmaphorum.com/news/new-combination-trial-firms-up-venclextas-prospects-in-aml/

News/ News/ Oncology/ Top stories

AbbVie/Roche’s Venclexta fails in confirmatory AML trial

Richard Staines AbbVie, acute myeloid leukaemia, cancer, Roche, Venclexta 0 Comment

AbbVie and Roche’s Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial

AbbVie/Roche’s Venclexta fails in confirmatory AML trial

https://pharmaphorum.com/news/abbvie-roches-venclexta-fails-in-confirmatory-aml-trial/

News/ News/ Oncology

Roche and AbbVie’s Venclexta approved in CLL

George Underwood AbbVie, CLL, Genentech, leukaemia, Roche, Venclexta, venetoclax 0 Comment

Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for

Roche and AbbVie’s Venclexta approved in CLL

https://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/

News/ News/ R&D

AbbVie/Roche seek first-line CLL use for Venclexta combo

Phil Taylor AbbVie, CLL, Roche, Venclexta 0 Comment

AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new

AbbVie/Roche seek first-line CLL use for Venclexta combo

https://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/

News/ News/ R&D

AbbVie, Roche eye first-line use of Venclexta in leukaemia

Phil Taylor AbbVie, leukaemia, R&D, Roche, Venclexta 0 Comment

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into

AbbVie, Roche eye first-line use of Venclexta in leukaemia

https://pharmaphorum.com/news/abbvie-roche-venclexta-leukaemia/

Clinical/ News/ Sales and Marketing

AbbVie/Roche’s Venclexta produces complete remission in 10% of hard-to-treat CLL patients

Richard Staines AbbVie, CLL, Oncology, Roche, Venclexta 0 Comment

AbbVie/Roche’s Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation,

AbbVie/Roche’s Venclexta produces complete remission in 10% of hard-to-treat CLL patients

https://pharmaphorum.com/transversal-categories/clinical/abbvie-roche-s-potential-blockbuster-venclexta-boosted-by-phase-ii-cll-results/

Trending

Venclexta

Login